Trials / Completed
CompletedNCT03231748
Clearance of Inflammatory Cytokines During Renal Replacement Therapy Using the EMIC®2 Filter
Clearance of Inflammatory Cytokines in Patients With Septic Acute Kidney Injury During Renal Replacement Therapy Using the EMIC®2 Filter
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 12 (actual)
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will be conducted in patients with sepsis and acute kidney injury needing renal replacement therapy. The aim is to investigate whether continuous renal replacement therapy with the EMIC®2 filter leads to removal of pro-inflammatory middle molecular weight cytokines from the blood.
Detailed description
In patients with acute kidney injury (AKI) and sepsis requiring renal replacement therapy, the investigators aim to determine whether continuous veno-venous haemodialysis with an EMiC®2 filter leads to clearance of the following mediators Interleukin (IL) -1 alpha, IL-1 beta, IL-2, IL- 4, IL-6, IL-8, IL-10, Tissue necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF), Interferon gamma, Monocyte chemotactic protein-1 and epidermal growth factor.
Conditions
Timeline
- Start date
- 2017-07-01
- Primary completion
- 2018-07-01
- Completion
- 2018-07-01
- First posted
- 2017-07-27
- Last updated
- 2019-10-23
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03231748. Inclusion in this directory is not an endorsement.